hepatocellular carcinoma
Conditions
Interventions
TRG 1a:none
TRG 1b:none
TRG 2:none
TRG 3:none
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
20 Years to 85 Years
Inclusion criteria
Inclusion criteria: a. Age between 18 and 65 years (including patients aged 18 years) b. Clinical diagnosis is hepatocellular carcinoma (According to the diagnosis and treatment guidelines for primary liver cancer (2022 edition) diagnostic criteria: HBV or HCV infection or cirrhosis caused by any cause, liver nodules = 2 cm in diameter were found, multi-parameter MRI, dynamic enhanced CT, contrast-enhanced ultrasound or hepatocyte specific contrast agent Gd-EOB-DTPA enhanced MRI showed at least 2 typical features of "fast forward and fast out" of liver cancer; or the presence of intrahepatic nodules> 2 cm in diameter, as long as one of the above four imaging examinations has typical liver cancer characteristics; serum AFP is elevated, especially continuously elevated, and only one of the above four imaging examinations has typical liver cancer characteristics; liver biopsy is definitely diagnosed as HCC) c. For patients with BCLC stage B or C, the first treatment received by the patient was intervention, molecular-targeted drugs, immunotherapy, systemic chemotherapy, etc., and the lesion could be radical surgical resection under imaging evaluation after treatment. d. Normal or downgraded liver function meeting surgical criteria (Child-Pugh A or screening Child-Pugh B liver function, ICG-R15 <14%, ECOG performance score 0-1) e. Can tolerate surgery under general anesthesia
Exclusion criteria
Exclusion criteria: a. Combined with other malignant tumors b. Patients who did not meet the criteria for conversion surgery after comprehensive treatment, or who did not complete a treatment cycle and withdrew c. The pathological margin after operation did not reach the R0 resection standard d. There are serious functional disorders of heart, brain, lung, kidney and other important organ systems; e. Missing clinicopathological data and uncooperative follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological tumor regression grade;recurrence-free survival;overall survival;postoperative complication; | — |
Countries
China
Contacts
Public ContactWei Yonggang
West China Hospital, Sichuan University
Outcome results
None listed